A5037736817- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Immune Cell Function and Interaction
- Genomics, phytochemicals, and oxidative stress
- Sirtuins and Resveratrol in Medicine
- Cancer-related gene regulation
- Synthetic Organic Chemistry Methods
- Cancer Immunotherapy and Biomarkers
- Bioactive Compounds and Antitumor Agents
- Immunotherapy and Immune Responses
- Traditional and Medicinal Uses of Annonaceae
- HIV/AIDS Research and Interventions
- CAR-T cell therapy research
- T-cell and B-cell Immunology
The Wistar Institute
2020-2023
Abstract Accurate characterization of the human immunodeficiency virus (HIV) reservoir is imperative to develop an effective cure. HIV was measured in antiretroviral therapy-suppressed individuals using intact proviral DNA assay (IPDA), along with assays for total or integrated DNA, and inducible RNA p24. Intact provirus correlated HIV.
Despite effective combination antiretroviral therapy (cART), people living with HIV (PLWH) continue to harbor replication-competent and transcriptionally active virus in infected cells, which turn can lead ongoing viral antigen production, chronic inflammation, increased risk of age-related comorbidities. To identify new agents that may inhibit postintegration beyond cART, we screened a library 512 pure compounds derived from natural products identified (–)-hopeaphenol as an inhibitor...
Despite the success of combination antiretroviral therapy (cART), HIV persists in low- and middle-income countries (LMIC) due to emerging drug resistance insufficient accessibility. Furthermore, cART does not target latently-infected CD4+ T cells, which represent a major barrier eradication. The “shock kill” therapeutic approach aims reactivate provirus expression cells presence virus-expressing for elimination. An attractive prototype LMICs would therefore be capable simultaneously...
Abstract Inhibition of the BCL6 BTB domain results in killing Diffuse Large B‐cell Lymphoma (DLBL) cells, reducing T‐cell dependent germinal center (GC) reaction mice, and reversing GC hyperplasia nonhuman primates. The available BTB‐specific inhibitors are poorly water soluble, thus, limiting their absorption vivo our understanding therapeutic strategy targeting GC. We synthesized a prodrug (AP‐4‐287) from potent inhibitor (FX1) with improved aqueous solubility pharmacokinetics (PK) mice....